Literature DB >> 26911559

Stress ulcer prophylaxis in critical illness: a Canadian survey.

Melissa Shears1, Waleed Alhazzani2, John C Marshall3, John Muscedere4, Richard Hall5, Shane W English6, Peter M Dodek7, François Lauzier8, Salmaan Kanji9,10, Mark Duffett11, Jeffrey Barletta12, Mohammed Alshahrani13, Yaseen Arabi14, Adam Deane15, Deborah J Cook16.   

Abstract

PURPOSE: Stress ulcer prophylaxis (SUP) using histamine-2-receptor antagonists has been a standard of care in intensive care units (ICUs) for four decades. Proton pump inhibitors (PPIs) are increasingly used despite apparently lower background rates of gastrointestinal bleeding and growing concerns about PPI-associated complications. Our objective was to understand the views and prescribing habits amongst Canadian physicians regarding SUP in the ICU and to gauge interest in a future randomized-controlled trial (RCT).
METHODS: We created a short self-administered survey about SUP for critically ill adults, evaluated its clinical sensibility, and pilot tested the instrument. We surveyed all physician members of the Canadian Critical Care Trials Group (CCCTG) by e-mail and sent reminders three and five weeks later.
RESULTS: We received 94 of 111 (85%) surveys from the validated respondent pool between May and June, 2015. Respondents reported use of SUP most commonly in patients 1) receiving invasive mechanical ventilation (62, 66%), 2) expected to be ventilated for ≥ two days (25, 27%), or 3) receiving mechanical ventilation but nil per os (NPO) (20, 21%). Stress ulcer prophylaxis is discontinued when patients no longer receive mechanical ventilation (75%), no longer are NPO (22%), or are discharged from the ICU (19%). Stress ulcer prophylaxis involves PPIs in 68% of centres. Most respondents endorsed the need for a large rigorous RCT of PPI vs placebo to understand the risks and benefits of this practice.
CONCLUSIONS: Stress ulcer prophylaxis is reportedly used primarily for the duration of mechanical ventilation. The CCCTG physicians believe that a placebo-controlled RCT is needed to evaluate the effectiveness and safety of contemporary SUP with PPIs.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26911559     DOI: 10.1007/s12630-016-0612-3

Source DB:  PubMed          Journal:  Can J Anaesth        ISSN: 0832-610X            Impact factor:   5.063


  10 in total

Review 1.  Stress Ulcer Prophylaxis in Neurocritical Care.

Authors:  Jeffrey F Barletta; Alicia J Mangram; Joseph F Sucher; Victor Zach
Journal:  Neurocrit Care       Date:  2018-12       Impact factor: 3.210

2.  Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016.

Authors:  Andrew Rhodes; Laura E Evans; Waleed Alhazzani; Mitchell M Levy; Massimo Antonelli; Ricard Ferrer; Anand Kumar; Jonathan E Sevransky; Charles L Sprung; Mark E Nunnally; Bram Rochwerg; Gordon D Rubenfeld; Derek C Angus; Djillali Annane; Richard J Beale; Geoffrey J Bellinghan; Gordon R Bernard; Jean-Daniel Chiche; Craig Coopersmith; Daniel P De Backer; Craig J French; Seitaro Fujishima; Herwig Gerlach; Jorge Luis Hidalgo; Steven M Hollenberg; Alan E Jones; Dilip R Karnad; Ruth M Kleinpell; Younsuk Koh; Thiago Costa Lisboa; Flavia R Machado; John J Marini; John C Marshall; John E Mazuski; Lauralyn A McIntyre; Anthony S McLean; Sangeeta Mehta; Rui P Moreno; John Myburgh; Paolo Navalesi; Osamu Nishida; Tiffany M Osborn; Anders Perner; Colleen M Plunkett; Marco Ranieri; Christa A Schorr; Maureen A Seckel; Christopher W Seymour; Lisa Shieh; Khalid A Shukri; Steven Q Simpson; Mervyn Singer; B Taylor Thompson; Sean R Townsend; Thomas Van der Poll; Jean-Louis Vincent; W Joost Wiersinga; Janice L Zimmerman; R Phillip Dellinger
Journal:  Intensive Care Med       Date:  2017-01-18       Impact factor: 17.440

3.  Pharmacological interventions for prevention and treatment of upper gastrointestinal bleeding in newborn infants.

Authors:  Daniel Stephen Green; Mohamed E Abdel-Latif; Lisa J Jones; Kei Lui; David A Osborn
Journal:  Cochrane Database Syst Rev       Date:  2019-07-02

4.  Efficacy and safety of proton pump inhibitors versus histamine-2 receptor blockers in the cardiac surgical population: insights from the PEPTIC trial.

Authors:  Sean van Diepen; Tim Coulson; Xiaoming Wang; Dawn Opgenorth; Danny J Zuege; Jo Harris; Malik Agyemang; Daniel J Niven; Rinaldo Bellomo; Stephen E Wright; Paul J Young; Sean M Bagshaw
Journal:  Eur J Cardiothorac Surg       Date:  2022-07-11       Impact factor: 4.534

5.  Combined application of nasogastric tubes and nasointestinal tubes in neurosurgical intensive care patients with stress ulceration: a novel solution to treatment and early enteral nutrition.

Authors:  Tianshu Lu; Jingyu Guan
Journal:  Springerplus       Date:  2016-10-12

6.  CYP2C19 Gene Profiling as a Tool for Personalized Stress Ulcer Prophylaxis With Proton Pump Inhibitors in Critically Ill Patients - Recommendations Proposal.

Authors:  Petra Bořilová Linhartová; Ondřej Zendulka; Jaroslav Janošek; Natálie Mlčůchová; Michaela Cvanová; Zdeněk Daněk; Radek Kroupa; Ladislava Bartošová; Břetislav Lipový
Journal:  Front Med (Lausanne)       Date:  2022-07-11

7.  Involvement of microRNA/cystine/glutamate transporter in cold-stressed gastric mucosa injury.

Authors:  You-Cong Yin; Xiao-Hui Li; Xuan Rao; Yuan-Jian Li; Jie Du
Journal:  Front Pharmacol       Date:  2022-09-28       Impact factor: 5.988

8.  Need for a Randomized Controlled Trial of Stress Ulcer Prophylaxis in Critically Ill Children: A Canadian Survey.

Authors:  Mark Duffett; Karen Choong; Jennifer Foster; Elaine Gilfoyle; Jacques Lacroix; Deborah J Cook
Journal:  Can J Hosp Pharm       Date:  2017-08-31

Review 9.  Stress ulcer prophylaxis in intensive care unit patients receiving enteral nutrition: a systematic review and meta-analysis.

Authors:  Hui-Bin Huang; Wei Jiang; Chun-Yao Wang; Han-Yu Qin; Bin Du
Journal:  Crit Care       Date:  2018-01-28       Impact factor: 9.097

10.  Effects of oral/enteral nutrition alone versus plus pantoprazole on gastrointestinal bleeding in critically ill patients with low risk factor: a multicenter, randomized controlled trial

Authors:  Kürşat Gündoğan; Emre Karakoc; Turgut Teke; Avşar Zerman; Aliye Esmaoglu; Şahin Temel; Muhammet Güven; Murat Sungur
Journal:  Turk J Med Sci       Date:  2020-06-23       Impact factor: 0.973

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.